Evidence of Benefit
Evidence of screening effect derives from descriptive studies of local and national programs in Japan,uncontrolled pilot experiences at a number of sites in Europe and the United States,and population-based studies in Canada and Germany.[ 1,2,3,4,5,6 ] [ 7 ] An increase in survival rates among screen-detected cases would be expected if screening was detecting neuroblastoma at an ...
General Information About Childhood Ependymoma
Childhood ependymoma is a disease in which malignant (cancer) cells form in the tissues of the brain and spinal cord. The brain controls vital functions such as memory and learning,the senses (hearing,sight,smell,taste,and touch),and emotion. The spinal cord is made up of bundles of nerve fibers that connect the brain with nerves in most parts of the body. About 1 in 11 childhood brain ...
PDQ IS A COMPREHENSIVE CANCER DATABASE AVAILABLE ON NCI'S WEB SITE. PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health,the federal government's focal point for biomedical research. .
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Childhood Brain and Spinal Cord Tumors Treatment Overview
General Information About Childhood Brain and Spinal Cord Tumors
A childhood brain or spinal cord tumor is a disease in which abnormal cells form in the tissues of the brain or spinal cord. There are many types of childhood brain and spinal cord tumors. The tumors are formed by the abnormal growth of cells and may begin in different areas of the brain or spinal cord. Tumors may be benign (noncancerous) or malignant (cancerous). Together,the brain and ...
Recurrent Pituitary Tumors Treatment
Standard Treatment Options for Recurrent Pituitary TumorsStandard treatment options for recurrent pituitary tumors include the following:Radiation therapy for postsurgical recurrence, which offers a high likelihood of local control.[1,2]Reirradiation, which provides long-term local control and control of visual symptoms.The question and selection of further treatment for patients who relapse is dependent on many factors, including the specific type of pituitary tumor, prior treatment, visual and hormonal complications, and individual patient considerations. Treatment Options Under Clinical Evaluation for Recurrent Pituitary TumorsTreatment options under clinical evaluation for recurrent pituitary tumors include the following:Stereotactic radiation surgery.[4,5,6]Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent pituitary tumor. The list of clinical trials can be further narrowed by
Treatment Option Overview
Surgical removal is recommended for most types of brain tumors,in most locations,and their removal should be as complete as possible within the constraints of preservation of neurologic function.[ 1 ] An exception to this role for surgery is deep-seated tumors such as pontine gliomas,which are diagnosed on clinical evidence and treated without initial surgery approximately 50% of the time. In ...
Changes to this Summary (11 / 16 / 2012)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.General InformationAdded text to state that ATRX is involved in epigenetic gene silencing and telomere length; ATRX mutation without MYCN amplification is associated with age at diagnosis in adolescents and young adults with metastatic neuroblastoma (cited Cheung et al. as reference 48).Added Schleiermacher et al. as reference 56.Stage InformationRevised text to state that before resection of the primary tumor, bone should be assessed by metaiodobenzylguanidine (MIBG) scan, which is applicable to all sites of disease, and by technetium 99 scan if the results of the MIBG scan are negative or unavailable. Also added text to state that additional imaging of isolated or equivocal positive lesions is recommended if the primary tumor does not take up MIBG (cited Taggart et al. as reference 5).Revised
Get More Information From NCI
Sources of further information about Adult Brain Tumors
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Adult Brain Tumors Treatment